GATE Biotechnology Syllabus 2026: Aspiring participants of the GATE 2026 Biotechnology (BT) exam must go through the GATE Biotechnology Syllabus. The detailed syllabus for GATE 2026 Biotechnology has ...
While the city is emerging from the pandemic as a hub for life sciences companies, real estate developers are racing to keep up with demand for pre-built labs. Taconic Partners and Silverstein ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company last year raised a ...
Since Bill Gates left his position with Microsoft (NASDAQ:MSFT) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interest. Gates was one of the ...
GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody
Oncology biotech Atreca is licensing its preclinical monoclonal antibody to the Bill & Melinda Gates Medical Research Institute, or MRI, for the potential treatment of malaria, a deadly disease that ...
Hosted on MSN
GATE Exam Analysis 2025, February 16: Check Shift 1, 2 Branch Wise Paper Review, Difficulty Level
GATE 2025 Paper Analysis: The GATE 2025 exam was conducted by the Indian Institute of Technology, Roorkee on February 01, 02, 15 and 16, 2025, at designated test centres spread across 8 exam zones.
Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust. For the purpose of this article, Benzinga will delve into the ...
A Seattle DNA analysis startup is taking on a project with global ambitions with $5.5 million in new funds from the Bill & Melinda Gates Foundation and the U.S. National Institutes of Health. Phase ...
Microsoft Corp. Founder Bill Gates is known as an all-around smart guy, but he’s a man of many hats. Gates is also an astute investor with diverse holdings in numerous sectors. As you might imagine, ...
It turns out that bacteria could hold a key to transforming how doctors treat disease -- at least that's what Editas, a privately held company that just raised $120 million from investors including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results